Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Ligand Pharma ( (LGND) ) has shared an update.
On September 12, 2025, Ligand Pharmaceuticals amended its Credit Agreement to extend the maturity date to September 12, 2028, and adjusted the minimum consolidated EBITDA covenant. This amendment is expected to impact the company’s financial operations by ensuring liquidity and stability, which may influence its market positioning and reassure stakeholders about its financial health.
The most recent analyst rating on (LGND) stock is a Buy with a $190.00 price target. To see the full list of analyst forecasts on Ligand Pharma stock, see the LGND Stock Forecast page.
Spark’s Take on LGND Stock
According to Spark, TipRanks’ AI Analyst, LGND is a Neutral.
Ligand Pharma’s strong earnings call performance and technical analysis indicators are the most significant factors driving the stock score. The company’s strategic investments and increased financial guidance highlight its growth potential. However, financial performance and valuation concerns, such as declining revenue and a negative P/E ratio, present risks that temper the overall score.
To see Spark’s full report on LGND stock, click here.
More about Ligand Pharma
Ligand Pharmaceuticals is a company operating in the pharmaceutical industry, focusing on developing and acquiring technologies that aid in drug discovery and development.
Average Trading Volume: 222,960
Technical Sentiment Signal: Buy
Current Market Cap: $3.24B
For an in-depth examination of LGND stock, go to TipRanks’ Overview page.